Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from China Bozza Development Holdings Limited ( (HK:1069) ) is now available.
China Health Technology Group reported interim unaudited revenue of RMB34.4 million for the six months ended 31 December 2025, up from RMB31.1 million a year earlier, as gross profit rose to RMB4.1 million from RMB2.8 million. Profit for the period edged up to RMB5.3 million from RMB5.0 million, supported by stable other gains and lower administrative expenses, while finance costs increased and basic earnings per share declined on a restated basis.
Total comprehensive income slipped to RMB5.4 million from RMB6.4 million, mainly due to a smaller positive exchange translation effect compared with the previous period. The figures indicate modest top-line growth and resilient profitability despite higher financing costs, suggesting that the group is maintaining operational efficiency while facing currency fluctuations and capital cost pressure that stakeholders will need to monitor.
The most recent analyst rating on (HK:1069) stock is a Hold with a HK$0.45 price target. To see the full list of analyst forecasts on China Bozza Development Holdings Limited stock, see the HK:1069 Stock Forecast page.
More about China Bozza Development Holdings Limited
China Health Technology Group Holding Company Limited operates in the health technology sector, generating revenue primarily from the sale of health-related products and services. The group focuses on the Mainland China market, leveraging its technology-driven offerings to capture demand in medical and wellness-related segments.
Average Trading Volume: 220,472
Technical Sentiment Signal: Sell
Current Market Cap: HK$43.74M
Learn more about 1069 stock on TipRanks’ Stock Analysis page.